Association Between Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19


This meta-analysis pools data from 7 randomized trials to estimate the association between administration of corticosteroids vs usual care or placebo and all-cause mortality at 28 days in patients with severe coronavirus disease 2019 (COVID-19).

Fonte: Association Between Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19

Covid-19: Do many people have pre-existing immunity?

www.bmj.com/content/bmj/370/bmj.m3563.full.pdf

It seemed a truth universally acknowledged that the human population had no pre-existing immunity to SARS-CoV-2, but is that actually the case? Peter Doshi explores the emerging research on immunological responses.

Case Report: Recurrent Clinical Symptoms of COVID-19 in Healthcare Professionals: A Series of Cases from Brazil

We describe six cases of healthcare professionals in Brazil who recovered but again presented symptoms consistent with COVID-19, with new positive reverse transcription (RT)-PCR test results.

COVID-19 is, in the end, an endothelial disease | European Heart Journal | Oxford Academic

Abstract. The vascular endothelium provides the crucial interface between the blood compartment and tissues, and displays a series of remarkable properties tha
— Ler em academic.oup.com/eurheartj/article/41/32/3038/5901158

Thrombosis and COVID-19 pneumonia: the clot thickens!


https://erj.ersjournals.com/content/56/1/2001608

A trombose pulmonar parece ser comum na pneumonia COVID-19 e assume duas formas, embolia pulmonar proximal e / ou trombose distal. Os possíveis mecanismos e implicações clínicas são discutidos.

CDC publica novas diretrizes de isolamento para COVID-19

Fonte: Coronavirus Disease 2019 (COVID-19)

A evidência acumulada apóia o fim do isolamento e as precauções para pessoas com COVID-19 usando uma estratégia baseada em sintomas. Esta atualização incorpora evidências recentes para informar a duração do isolamento e as precauções recomendadas para impedir a transmissão do SARS-CoV-2 a outras pessoas, além de limitar o isolamento prolongado desnecessário e o uso desnecessário de recursos de testes de laboratório.

NEJM – Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19


https://www.nejm.org/doi/full/10.1056/NEJMoa2019014?query=RP

Saindo do forno! Estudo multicêntrico brasileiro que acaba de ser disponibilizado na edição online. Mais um prego no caixão da cloroquina.

 

 

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM


Original Article from The New England Journal of Medicine — Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Fonte: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM

Saindo do forno o trabalho sobre o benefício do corticoide em pacientes com COVID. Ansiosamente aguardado!!

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19


https://www.acpjournals.org/doi/10.7326/M20-4207

Conclusão:
A hidroxicloroquina não reduziu substancialmente a gravidade dos sintomas em pacientes ambulatoriais com COVID-19 leve e precoce.

Pulmonary embolism in COVID-19 patients: a French multicentre cohort study


https://academic.oup.com/eurheartj/article/doi/10.1093/eurheartj/ehaa500/5870571

Conclusão
Os fatores de risco para EP no contexto COVID-19 não incluem fatores de risco tromboembólicos tradicionais, mas sim achados clínicos e biológicos independentes na admissão, incluindo uma importante contribuição para a inflamação.